Plumestars’ participation at R2B – Research to Business 2017 at Bologna Fiere

On June 8th, the 11th edition of the Innovation & Match 2017 was held, the intermediation event with bilateral meetings between companies, research centers and universities, organized by ASTER and Emilia-Romagna Enterprise Europe Network partners of the SIMPLER consortium.

The event took place within R2B – Research to Business 2017, the 12th edition of the International Industrial Research Exhibition, promoted by the Emilia-Romagna Region, Bologna Fiere, ASTER and SMAU.

R2B 2017 aims to foster new business opportunities between research and business systems since 2005.

PlumeStars actively participated in the event, meeting potential customers and presenting the following products:

  1. A breathable antibacterial amikacin powder for pulmonary infections in cystic fibrosis. Innovation in this product has been achieved by building a powder of amikacin with high drug content to be administered with a dry powder inhaler.
  2. A film of hyaluronic acid loaded with cisplatin to be implanted in the operative site immediately after surgery of pleural mesothelioma. The film covers the pleural cavity where it slowly releases the drug to locally maintain its cytostatic effect for a long time, at the site where recurrences occur frequently.
  3. A thalidomide powder preparation to be used in oral / nasal therapy of hereditary hemorrhagic telangiectasia, a disease that causes frequent and abundant bleeding from the nose. PlumeStars has proposed to prolong the beneficial effect demonstrated in human by thalidomide oral treatment, administering the drug directly to the nasal cavity.




PlumeStars attended the 57th AFI Symposium

PlumeStars actively participated at the 57th AFI Symposium, the Italian Conference of the Industrial Pharmacists, held on 7-8 and 9 June at the Pala Congressi in Rimini. The symposium has registered more than 1000 attendees and more than 100 stands, reconfirming itself as a meeting point for excellence which revolves around the pharmaceutical world.

The 57th AFI Symposium organized the “Startup Square”, an area specifically dedicated within the exhibition space and accessible for free to allow visitors and companies to come in direct contact with the innovative realities present.

PlumeStars presented in a speech of Prof. Paolo Colombo (PlumeStars CEO) The Orphan Medicine Initiative, describing important achievements in the field of orphan medicines. The novel orphan medicines presented in Rimini were:

  • Amikacin & tobramycin powders for inhalations in cystic fibrosis
  • Cisplatin films for local delivery in mesothelioma recurrences
  • Thalidomide powder for oral and nasal delivery in Hereditary Haemorrhagic Telangiectasia.